Payment overview · 2025
General Payments
$365.27
16 reported records · 10 companies
Healthcare provider profile · identity verified
Raul Holguin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VENICE, FL · NPI 1295733178
Verified facts
What the public records show
CMS Open Payments records show Raul Holguin, M.D. received $365.27 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.02 | 20.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.57 | 14.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.09 | 14.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.11 | 11.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.33 | 9.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.10 | 9.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.54 | 5.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.21 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.97 | 5.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.33 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.27 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 242 |
| Lisinopril | Lisinopril | 483 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 108 |
| Omeprazole | Omeprazole | 296 | 84 |
| Trazodone Hcl | Trazodone Hcl | 272 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 80 |
| Metformin Hcl | Metformin Hcl | 212 | 68 |
| Losartan Potassium | Losartan Potassium | 209 | 65 |
| Sertraline Hcl | Sertraline Hcl | 207 | 69 |
| Gabapentin | Gabapentin | 206 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 62 |
| Simvastatin | Simvastatin | 186 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 60 |
| Bupropion Xl | Bupropion Hcl | 130 | 42 |
| Tramadol Hcl | Tramadol Hcl | 120 | 30 |
| Alendronate Sodium | Alendronate Sodium | 119 | 43 |
| Furosemide | Furosemide | 115 | 36 |
| Allopurinol | Allopurinol | 107 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 30 |
| Potassium Chloride | Potassium Chloride | 105 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 47 |
| Eliquis | Apixaban | 100 | 32 |
| Prednisone | Prednisone | 91 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 17 |
| Carvedilol | Carvedilol | 69 | 24 |
| Alprazolam | Alprazolam | 67 | 24 |
| Atenolol | Atenolol | 66 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 19 |
| Topiramate | Topiramate | 62 | 24 |
| Famotidine | Famotidine | 60 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Meloxicam | Meloxicam | 55 | 34 |
| Myrbetriq | Mirabegron | 52 | 12 |
| Finasteride | Finasteride | 46 | 16 |
| Lorazepam | Lorazepam | 46 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 31 |
| Spironolactone | Spironolactone | 41 | 16 |
| Mirtazapine | Mirtazapine | 39 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 14 |
| Glimepiride | Glimepiride | 38 | 13 |
| Ramipril | Ramipril | 37 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 15 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.27 · 16 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error